These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 27802968)
1. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Fucikova J; Truxova I; Hensler M; Becht E; Kasikova L; Moserova I; Vosahlikova S; Klouckova J; Church SE; Cremer I; Kepp O; Kroemer G; Galluzzi L; Salek C; Spisek R Blood; 2016 Dec; 128(26):3113-3124. PubMed ID: 27802968 [TBL] [Abstract][Full Text] [Related]
2. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Wemeau M; Kepp O; Tesnière A; Panaretakis T; Flament C; De Botton S; Zitvogel L; Kroemer G; Chaput N Cell Death Dis; 2010 Dec; 1(12):e104. PubMed ID: 21368877 [TBL] [Abstract][Full Text] [Related]
3. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Truxova I; Kasikova L; Salek C; Hensler M; Lysak D; Holicek P; Bilkova P; Holubova M; Chen X; Mikyskova R; Reinis M; Kovar M; Tomalova B; Kline JP; Galluzzi L; Spisek R; Fucikova J Haematologica; 2020 Jul; 105(7):1868-1878. PubMed ID: 31582537 [TBL] [Abstract][Full Text] [Related]
4. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Fredly H; Ersvær E; Gjertsen BT; Bruserud O Oncol Rep; 2011 Jun; 25(6):1549-56. PubMed ID: 21431284 [TBL] [Abstract][Full Text] [Related]
5. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823 [TBL] [Abstract][Full Text] [Related]
6. The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients. Mans S; Banz Y; Mueller BU; Pabst T Blood; 2012 Sep; 120(13):2690-9. PubMed ID: 22915645 [TBL] [Abstract][Full Text] [Related]
7. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Le Dieu R; Taussig DC; Ramsay AG; Mitter R; Miraki-Moud F; Fatah R; Lee AM; Lister TA; Gribben JG Blood; 2009 Oct; 114(18):3909-16. PubMed ID: 19710498 [TBL] [Abstract][Full Text] [Related]
8. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661 [TBL] [Abstract][Full Text] [Related]
9. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia. Yang T; Chen ZZ; Kolb HJ; Buhmann R Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564 [TBL] [Abstract][Full Text] [Related]
10. Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis. Serrano Del Valle A; Beltrán-Visiedo M; de Poo-Rodríguez V; Jiménez-Alduán N; Azaceta G; Díez R; Martínez-Lázaro B; Izquierdo I; Palomera L; Naval J; Anel A; Marzo I Oncoimmunology; 2022; 11(1):2141973. PubMed ID: 36338146 [TBL] [Abstract][Full Text] [Related]
11. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. D'Eliseo D; Manzi L; Velotti F Cell Stress Chaperones; 2013 Nov; 18(6):801-8. PubMed ID: 23580156 [TBL] [Abstract][Full Text] [Related]
12. Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML. Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H J Investig Med; 2016 Dec; 64(8):1252-1260. PubMed ID: 27388616 [TBL] [Abstract][Full Text] [Related]
13. Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Weidmann E; Brieger J; Jahn B; Hoelzer D; Bergmann L; Mitrou PS Ann Hematol; 1995 Mar; 70(3):153-8. PubMed ID: 7718644 [TBL] [Abstract][Full Text] [Related]
14. Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. Fucikova J; Kasikova L; Truxova I; Laco J; Skapa P; Ryska A; Spisek R Immunol Lett; 2018 Jan; 193():25-34. PubMed ID: 29175313 [TBL] [Abstract][Full Text] [Related]
15. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Sen Santara S; Lee DJ; Crespo Â; Hu JJ; Walker C; Ma X; Zhang Y; Chowdhury S; Meza-Sosa KF; Lewandrowski M; Zhang H; Rowe M; McClelland A; Wu H; Junqueira C; Lieberman J Nature; 2023 Apr; 616(7956):348-356. PubMed ID: 37020026 [TBL] [Abstract][Full Text] [Related]
16. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Munker R; Andreeff M Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699 [TBL] [Abstract][Full Text] [Related]
17. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Coles SJ; Hills RK; Wang EC; Burnett AK; Man S; Darley RL; Tonks A Leukemia; 2012 Sep; 26(9):2148-51. PubMed ID: 22430635 [No Abstract] [Full Text] [Related]
18. Targeting immunogenic cell death in cancer. Ahmed A; Tait SWG Mol Oncol; 2020 Dec; 14(12):2994-3006. PubMed ID: 33179413 [TBL] [Abstract][Full Text] [Related]
19. Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. Panzarini E; Inguscio V; Fimia GM; Dini L PLoS One; 2014; 9(8):e105778. PubMed ID: 25140900 [TBL] [Abstract][Full Text] [Related]
20. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Fredly H; Reikvam H; Gjertsen BT; Bruserud O Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]